Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
early stage clinical trial on Nov. 16 and its third-quarter earnings on Nov. 7.Usually, updates like those two would act as positive catalysts for a stock, assuming there was good news to share. In this case, there wasn't exactly any bad news, but the stock is clearly still smarting from the damage in October , when some clinical results from its gene editing program for hereditary angioedema (HAE) didn't stack up very favorably against a competitor's candidate. Are You Missing The Morning Scoop? Breakfast News delivers it all in a quick, Foolish, and free daily newsletter. Sign Up For Free » So is this stock still worth a purchase, or is there a problem that's starting to pick up speed? First, let's examine the most recent information produced by this biotech to see if there's anything overtly bearish. Intellia's investigational gene-editing therapy called nex-z (formerly known as NTLA-2001) aims to treat or cure a rare, progressive, and ultimately fatal hereditary illness
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $90.00 price target on the stock.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Wells Fargo & Company from $80.00 to $70.00. They now have an "overweight" rating on the stock.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $14.00 price target on the stock.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at William Blair. They now have a $14.00 price target on the stock.MarketBeat
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target raised by analysts at Chardan Capital from $88.00 to $91.00. They now have a "buy" rating on the stock.MarketBeat
NTLA
Earnings
- 11/7/24 - Beat
NTLA
Sec Filings
- 11/18/24 - Form 8-K
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- NTLA's page on the SEC website